Infectious Diseases Division Research

Research Focus Areas

Healthy Equity

• Kevin Ard, MD: HIV pre-exposure prophylaxis (PrEP) implementation and equity, sexually transmitted infections
• Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
• Scott Dryden-Peterson, MD MSc: Access to cancer screening and treatment for PWH; Access to COVID-19 therapeutics
• Louise C. Ivers, MBBCH, BAO, MD, MPH, DTM&H: Addressing barriers to the delivery of healthcare in rural, resource-poor settings
• Amir Mohareb, MD: Infection screening and prevention among refugees, immigrants, and asylum-seekers
• Bisola Ojikutu, MD, MPH: biomedical HIV prevention, racial and ethnic disparities in HIV-related outcomes

COVID-19

• Lindsey Baden, MD: COVID-19 vaccines and controlled trials of convalescent plasma
• Amy Barczak, MD: Viral dynamics of SARS-CoV-2 infection
• Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
• Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
• Richelle Charles, MD: Assessment of antibody profiles in COVID-19 patients; national/international seroepidemiology studies of at-risk populations
• Andrea Ciaranello, MD: Clinical outcomes, epidemiology, and simulation modeling in the United States and resource-limited settings
• Scott Dryden-Peterson, MD MSc: Real world effectiveness studies; Disparities; Risk of severe outcomes
• Marcia B. Goldberg, MD: High resolution analysis of immune responses to COVID-19
• Yonatan Grad, MD, PhD: COVID-19 epidemiology and the impact of interventions to slow and control spread
• Nicolas Issa, MD: Favipiravir for COVID-19
• Sanjat Kanjilal, MD: Performance characteristics of virologic and serologic assays for COVID-19
• Arthur Kim, MD: Clinical (hospitalized patients) and translational (immunology) research in COVID-19
• Camille Nelson Kotton, MD: Epidemiology of COVID-19 and immunocompromised hosts; impact of zanubrutinib on pulmonary distress in COVID-19
• Dan Kuritzkes, MD: Canakinumab for severe COVID-19; AT-527 (a novel purine analog) for moderate COVID-19
• Jonathan Li, MD, MMSc: HIV and SARS-CoV-2 drug resistance, persistence, and cure
• Anne Neilan, MD, MPH: COVID simulation modeling and pediatric COVID epidemiology
• Mark Poznansky, MD, PhD: Driving the development of a self-assembling vaccine candidate for protective immunity against SARS-CoV-2 and Influenza
• Edward Ryan, MD, DTM&H: Host-pathogen interactions, immune responses, and vaccine development for bacterial pathogens and COVID-19
• Erica Shenoy, MD, PhD: COVID-19 epidemiology, including nosocomial infection, healthcare worker infection, and levering informatics for infection prevention/control
• Mark Siedner, MD: COVID-19 surveillance in rural South Africa and impacts of control measures on older Ugandans
• Ann Woolley, MD: Observational study of patients with COVID-19 at BWH; tocilizumab for COVID-19

Antibiotics, Vaccines, Bacterial Diagnostics and Therapeutics

Vaccines & Therapeutics

• Richelle Charles, MD: Human immune responses to cholera and typhoid fever
• Elizabeth Hohmann, MD: Fecal transplantation for C. difficile and other indications
• Gerald Pier, PhD: Virulence and immunity to microbial pathogens
• Mark Poznansky, MD, PhD: Research and development of vaccines and immunotherapies for infectious diseases (including COVID-19 and flu), cancer including HPV induced cancer, Type 1 Diabetes, and neurodegenerative diseases like ALS
• Edward Ryan, MD, DTM&H: Host-pathogen interactions, immune reponses and vaccine development for bacterial pathogens
• Matthew Waldor, MD, PhD: Investigation of pathogen-host interactions in the context of animal models of infection

Antibiotic Resistance & Diagnostics

• Roby Bhattacharyya, MD, PhD: Antimicrobial resistance; microbial genomics and transcriptomics; rapid bacterial and fungal diagnostics; single-cell immune profiling in infection
• Marcia B. Goldberg, MD: Human Signatures for Diagnosis of Bacterial Infection
• Yonatan Grad, MD, PhD: Dynamics of pathogen evolution and spread
• David Hooper, MD: Mechanisms and epidemiology of antimicrobial resistance
• Deborah Hung, MD, PhD: In vivo mechanisms of bacterial pathogenesis and infectious disease diagnostics
• Erica Shenoy, MD, PhD: Optimizing infection control policy to improve patient care and resource allocation

Bacterial Pathogenesis

Molecular interactions of bacterial pathogens with host cells

• Amy Barczak, MD: Tuberculosis pathogenesis in cells and tissues
• Marcia Goldberg, MD: Bacterial host-pathogen interactions and rapid diagnostics of infection
• Deborah Hung, MD, PhD: In vivo mechanisms of bacterial pathogenesis and infectious disease diagnostics
• Matthew Waldor, MD, PhD: Investigation of pathogen-host interactions in the context of animal models of infection

Immune response to bacterial pathogens

• Pierre Ankomah, MD, PhD: Systems immunology of bacterial infections; Within-host microbial population and evolutionary dynamics
• Roby Bhattacharyya, MD, PhD: Single-cell immune profiling in sepsis
• Richelle Charles, MD: Human immune responses to cholera and typhoid fever
• Joseph ElKhoury, MD: Role of the innate immune system in neurodegeneration, inflammation, and infection
• Marcia Goldberg, MD: Bacterial host-pathogen interactions and rapid diagnostics of infection
• Jason Harris, MD: Human immune response to cholera and cholera vaccines
• Dennis Kasper, MD: Immune-pathogen interactions
• Regina LaRocque, MD, MPH: Host factors influencing susceptibility to cholera in endemic settings
• Gerald Pier, PhD: Virulence and immunity to microbial pathogens
• Edward Ryan, MD, DTM&H: Host-pathogen interactions, immune reponses and vaccine development for bacterial pathogens
• Matthew Waldor, MD, PhD: Investigation of pathogen-host interactions in the context of animal models of infection
• H. Shaw Warren, MD: Pathogenesis and treatment of sepsis and induced secondary inflammation

Microbiota

• Elizabeth Hohmann, MD: Fecal transplantation for C. difficile and other indications
• Dennis Kasper, MD: Immune-pathogen interactions
• Regina LaRocque, MD, MPH: Host factors influencing susceptibility to cholera in endemic settings
• Gerald Pier, PhD: Virulence and immunity to microbial pathogens
• Matthew Waldor, MD, PhD: Investigation of pathogen-host interactions in the context of animal models of infection

Tuberculosis

• Amy Barczak, MD: Tuberculosis pathogenesis in cells and tissues
• Sarah Fortune, MD: Molecular pathogenesis of tuberculosis infection
• Deborah Hung, MD, PhD: In vivo mechanisms of bacterial pathogenesis and infectious disease diagnostics
• Serena Koenig, MD, MPH: Clinical trials and observational studies to improve outcomes for people who are living with HIV and/or tuberculosis
• Eric Rubin, MD, PhD, MPH: Pathogenesis of tuberculosis

Hospital Epidemiology and Healthcare-Associated Infections

• Meghan Baker, MD: Surveillance and prevention of healthcare-associated infections, cluster detection and response
• David Hooper, MD: Mechanisms and epidemiology of antimicrobial resistance
• Michael Klompas, MD: Surveillance and prevention of infections in critically ill patients
• Richard Platt, MD, MSc: Comparative effectiveness and healthcare systems
• Chanu Rhee, MD, MPH: Epidemiology, surveillance, diagnosis, and prevention of sepsis and infections in critically ill patients
• Erica Shenoy, MD, PhD: Optimizing infection control policy to improve patient care and resource allocation

Global (HIV, enteric bacterial diseases)

HIV

• Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
• Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
• Andrea Ciaranello, MD: Strategies to improve the care of HIV-infected women, children, and adolescents
• Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
• Scott Dryden-Peterson, MD MSc: Effect of HIV on cancer risk and oncologic outcomes; Programmatic and implementation trials in HIV and cancer care; HIV treatment and prevention clinical trials (ACTG, IMPAACT, HPTN); Cervical cancer prevention trials (CASCADE)
• Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
• Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
• Serena Koenig, MD, MPH: Clinical trials and observational studies to improve outcomes for people who are living with HIV and/or tuberculosis
• Daniel Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
• Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
• Jonathan Li, MD, MMSc: HIV and SARS-CoV-2 drug resistance, persistence, and cure
• Shahin Lockman, MD: HIV in developing countries
• Anne Neilan, MD MPH: Epidemiology, health policy, and simulation modeling among adolescents and young adults living with and at risk of HIV
• Holly Rawizza, MD, MPH: Pharmacokinetic studies of HIV and TB drugs in children; Operational studies to improve HIV outcomes in Nigeria
• Mark Siedner, MD: Improving health and quality of life for people with HIV in sub-Saharan Africa
• Bruce Walker, MD: Cellular Mechanisms of HIV Control

Bacterial

• Richelle Charles, MD: Human immune responses to cholera and typhoid fever
• Jason Harris, MD: Human immune response to cholera and cholera vaccines
• Louise C. Ivers, MBBCH, BAO, MD, MPH, DTM&H: Addressing barriers to the delivery of healthcare in rural, resource-poor settings
• Amir Mohareb, MD: Investigating the interaction between infectious diseases, humanitarian crises, and global migration
• Regina LaRocque, MD, MPH: Host factors influencing susceptibility to cholera in endemic settings
• Edward Ryan, MD, DTM&H: Host-pathogen interactions, immune reponses and vaccine development for bacterial pathogens

Tuberculosis

• Amy Barczak, MD: Tuberculosis pathogenesis in cells and tissues
• Sarah Fortune, MD: Molecular pathogenesis of tuberculosis infection
• Holly Rawizza, MD, MPH: Pharmacokinetic studies of HIV and TB drugs in children
• Eric Rubin, MD, PhD, MPH: Pathogenesis of tuberculosis

HIV

Reservoirs and Eradication

• Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
• Rajesh Gandhi, MD: Studies of HIV reservoirs and immune-based therapies, including clinical trials
• Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
• Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
• Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
• Jonathan Li, MD: HIV drug resistance, persistence, and cure
• Mathias Lichterfeld, MD, PhD: HIV immune defense mechanisms and clinical development of HIV eradication/cure strategies
• Eric Rosenberg, MD: Mechanisms of successful cellular immune responses to HIV
• Athe Tsibris, MD: HIV reservoirs and cure

Vaccines

• Lindsey Baden, MD: Vaccines and infectious complications of immunosuppression
• Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
• Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
• Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
• Bruce Walker, MD: Cellular Mechanisms of HIV Control

Resistance and Clinical Trials

• Lindsey Baden, MD: Vaccines and infectious complications of immunosuppression
• Scott Dryden-Peterson, MD, MSc: Programmatic and implementation trials in HIV and cancer care; HIV treatment and prevention clinical trials (ACTG, IMPAACT, HPTN); Cervical cancer prevention trials (CASCADE)
• Rajesh Gandhi, MD: Studies of HIV reservoirs and immune-based therapies, including clinical trials
• Boris Juelg, MD, PhD: Immunotherapies for the prevention and treatment of infectious diseases
• Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
• Jonathan Li, MD: HIV drug resistance, persistence, and cure
• Mathias Lichterfeld, MD, PhD: HIV immune defense mechanisms and clinical development of HIV eradication/cure strategies
• Shahin Lockman, MD: HIV in developing countries
• Gregory Robbins, MD, MPH: Clinical decision support systems to improve HIV health outcomes
• Paul Sax, MD: Clinical trials and cost-effectiveness of HIV therapy
• Bruce Walker, MD: Cellular Mechanisms of HIV Control

Adherence

• Jenn Manne-Goehler, MD, ScD: HIV and metabolic disease
• Mark Siedner, MD: Improving health and quality of life for people with HIV in sub-Saharan Africa

International

• Dan Barouch, MD: HIV immunology and development of novel vaccine and eradication strategies
• Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
• Andrea Ciaranello, MD: Strategies to improve the care of HIV-infected women, children, and adolescents
• Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
• Scott Dryden-Peterson, MD, MSc: Effect of HIV on cancer risk and oncologic outcomes; Programmatic and implementation trials in HIV and cancer care; HIV treatment and prevention clinical trials (ACTG, IMPAACT, HPTN); Cervical cancer prevention trials (CASCADE)
• Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
• Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
• Dan Kuritzkes, MD: Studies on HIV therapeutics, antiretroviral drug resistance, HIV-1 persistence and eradication
• Douglas Kwon, MD, PhD: Host-microbe interactions in the gut, lung, and female genital tract in HIV infection
• Jonathan Li, MD, MMSc: HIV and SARS-CoV-2 drug resistance, persistence, and cure
• Shahin Lockman, MD: HIV in developing countries
• Jenn Manne-Goehler, MD, ScD: HIV and metabolic disease
• Anne Neilan, MD MPH: Epidemiology, health policy, and simulation modeling among adolescents and young adults living with and at risk of HIV
• Mark Siedner, MD: Improving health and quality of life for people with HIV in sub-Saharan Africa
• Bruce Walker, MD: Cellular Mechanisms of HIV Control

Modeling and Outcomes

• Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
• Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
• Andrea Ciaranello, MD: Strategies to improve the care of HIV-infected women, children, and adolescents
• Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
• Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
• Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
• Jenn Manne-Goehler, MD, ScD: HIV and metabolic disease
• Anne Neilan, MD MPH: Epidemiology, health policy, and simulation modeling among adolescents and young adults living with and at risk of HIV
• Paul Sax, MD: Clinical trials and cost-effectiveness of HIV therapy
• Virginia Triant, MD, MPH: Outcomes research on non-communicable/aging-related diseases and HIV

Outcomes Research and Health Policy

• Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
• Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
• Andrea Ciaranello, MD: Epidemiology, outcomes, and policy modeling for maternal-child health in HIV
• Caitlin Dugdale, MD: Simulation modeling and health policy to reduce vertical HIV transmission and improve global maternal-child health
• Kenneth Freedberg, MD, MSc: Clinical outcomes and health policy in chronic disease
• Emily Hyle, MD MSc DTM&H (Gorgas): Epidemiology, health policy, and simulation modeling in HIV and travel medicine
• Louise C. Ivers, MBBCH, BAO, MD, MPH, DTM&H: Addressing barriers to the delivery of healthcare in rural, resource-poor settings
• Amir Mohareb, MD: Hepatitis B screening and treatment guidelines in sub-Saharan Africa
• Anne Neilan, MD, MPH: Simulation modeling and health policy among adolescents living with and at risk of HIV
• Erica Shenoy, MD, PhD: Optimizing infection control policy to improve patient care and resource allocation
• Virginia Triant, MD, MPH: Outcomes research on non-communicable/aging-related diseases and HIV

Non HIV Virology

HCV

• Arthur Kim, MD: Clinical and translational research in HCV infection, particularly in special populations

Pathogenesis

• Benjamin Gewurz, MD, PhD: Genetic, Proteomic and Immunologic analysis of EBV lytic replication and B-cell transformation
• Kenneth Kaye, MD: Mechanisms of tumor virus persistence and pathogenesis

Vaccines

• Jonathan Abraham, MD, PhD: Antibody-based therapeutics and vaccines against emerging viruses

Fungal Pathogenesis, Diagnostics, and Therapeutics

• Roby Bhattacharyya, MD, PhD: Developing transcriptional diagnostics for rapid fungal identification and susceptibility testing
• Sarah Hammond, MD: Clinical research in invasive fungal infection and novel antifungal therapies; infections in hematologic malignancy
• Sophia Koo, MD: Metabolite-based methods for diagnosis and therapeutic efficacy assessment of pneumonia and other infections
• Michael Mansour, MD, PhD: Fungal cell wall carbohydrates in the development of host immune responses

Immunocompromised Hosts

• Lindsey Baden, MD: Vaccines and infectious complications of immunosuppression
• Jay Fishman, MD: Infections in xenotransplantation including porcine endogenous retrovirus and herpesviruses in primate hosts
• Benjamin Gewurz, MD, PhD: Genetic, Proteomic and Immunologic analysis of EBV lytic replication and B-cell transformation
• Sarah Hammond, MD: Clinical research in invasive fungal infection and novel antifungal therapies; infections in hematologic malignancy
• Kenneth Kaye, MD: Mechanisms of tumor virus persistence and pathogenesis
• Arthur Kim, MD: Immune responses to viruses and vaccines after checkpoint inhibitor therapy
• Sophia Koo, MD: Metabolite-based methods for diagnosis and therapeutic efficacy assessment of pneumonia and other infections
• Camille Nelson Kotton, MD: Vaccines, diagnostics and prevent of cytomegalovirus after organ and bone marrow transplant
• Jessica Little, MD: Vaccines, diagnostics and prevent of cytomegalovirus after organ and bone marrow transplant
• Michael Mansour, MD, PhD: Infections in immunocompromised hosts; antimicrobial stewardship
• Amy Sherman, MD: Vaccinations and respiratory viral infections in immunocompromised hosts

Fellowships and Training

ACGME-Certified Fellowship Training

The Massachusetts General and Brigham and Women's Hospitals have integrated their Infectious Disease Fellowship Training Programs to offer unparalleled opportunities for clinical and research training in Infectious Diseases at Harvard Medical School. For more information, visit the Infectious Diseases Fellowship Program website.

Post-doctoral research fellowships

Post-doctoral research fellows are supported by three separate NIH T32 research grants that are directed by MGB ID faculty:

1. 1. Laboratory-based HIV research (PI: Dr. Daniel Kuritzkes, T32 AI 157854): Potential areas of investigation include any HIV-related laboratory or translational research.
2. HIV clinical research (PI: Dr. Mark Siedner, T32 AI 007433): Potential areas of investigation include HIV-related clinical and/or population research, including clinical epidemiology, outcomes, implementation science, and health policy studies. This grant also frequently supports one slot each year that can support someone pursuing clinical research related to populations that does not necessarily focus explicitly on HIV but have shared risk factors (eg study of tuberculosis, HCV, sexually transmitted infections, and other related conditions)..
3. Fundamental investigation into infectious diseases and microbiology (PI Dr. Marcia Goldberg, T32 AI 007061): Potential areas of investigation include fundamental and/or epidemiological research relating to infectious diseases, its pathogenesis, and/or microbiology, not related to HIV.
   Support for post-doctoral fellows on these T32 grants includes salary or stipend, registration and travel to professional meetings, and other training-related expenses. Tuition for the Program in Clinical Effectiveness (PCE) at Harvard T.H. Chan School of Public Health or PhD coursework may be covered for some fellows. Applicants are nominated by a mentor who is an independently funded investigator. These research training programs are designed to support early career scientists with protected time, hands-on mentorship, and didactics to prepare them for careers in research careers, be they in academia or elsewhere.

Adult Infectious Disease & Basic Microbiologic Mechanisms Training Program

The Adult Infectious Disease and Basic Microbiological Mechanisms Training Program is a Harvard-wide training program dedicated to the education of those infectious disease fellows and PhD postdoctoral fellows interested in pursuing careers as physician-scientists or scientists with a focus on investigation into important questions in non-HIV microbiology and infectious diseases.

Transplant Infectious Disease & Compromised Host Fellowship

This program provides advanced training in the infectious disease management of solid organ and stem cell transplant recipients and patients with immunocompromises, i.e. hematopoietic malignancy, those following CAR-T and immunotherapies.

ID Elective for Medical Students

The monthly clinical elective in Infectious Diseases at Mass General Hospital is structured around the consultation services provided by the Infectious Disease Division.

Infectious Diseases in Adults 2025 CME Course

This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians.

Mass General Brigham ID Images

The Division of Infectious Diseases, in collaboration with the Mass General Brigham AIDS Research Center and the Division of Infectious Diseases at the Brigham and Women’s Hospital, has developed an online, case and image-based learning tool called Mass General Brigham Infectious Disease Images.

HIV Online Provider Education (HOPE)

The HIV Online Provider Education (HOPE) program is a twice-monthly conference involving several hundred doctors and nurses in Africa, Asia, the Caribbean, and other parts of the world. Each conference is also archived for later viewing.